Attached files

file filename
10-K - FORM 10-K - TRIMEDYNE INCtmed_10k-093012.htm
EX-32.1 - CERTIFICATION - TRIMEDYNE INCtmed_10k-ex3201.htm
EX-32.2 - CERTIFICATION - TRIMEDYNE INCtmed_10k-ex3202.htm
EX-31.2 - CERTIFICATION - TRIMEDYNE INCtmed_10k-ex3102.htm
EX-31.1 - CERTIFICATION - TRIMEDYNE INCtmed_10k-ex3101.htm
EXCEL - IDEA: XBRL DOCUMENT - TRIMEDYNE INCFinancial_Report.xls
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR2.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR8.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR1.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR5.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR3.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR4.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR7.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR9.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR41.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR18.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR53.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR54.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR47.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR19.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR16.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR17.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR52.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR33.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR37.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR34.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR51.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR49.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR12.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR21.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR38.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR15.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR22.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR14.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR45.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR44.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR25.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR42.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR39.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR32.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR48.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR10.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR36.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR40.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR55.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR46.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR35.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR28.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR20.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR24.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR23.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR30.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR27.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR11.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR13.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR31.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR26.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR29.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR43.htm
XML - IDEA: XBRL DOCUMENT - TRIMEDYNE INCR50.htm
v2.4.0.6
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
12 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Cash flows from operating activities:    
Net loss $ (836,000) $ (1,486,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Stock-based compensation 27,000 30,000
Depreciation and amortization 310,000 304,000
Amortization of debt discount 0 10,000
Change in fair value of derivative liabilities 0 (43,000)
Loss on extinguishment of related party note payable 0 36,000
Loss on disposal of fixed assets 0 3,000
Changes in operating assets and liabilities:    
Trade accounts receivable 105,000 93,000
Inventories 315,000 451,000
Other assets 119,000 120,000
Accounts payable (120,000) 141,000
Accrued expenses (77,000) (160,000)
Accrued interest to related party (1,000) (2,000)
Deferred revenue (40,000) 18,000
Accrued warranty (15,000) 21,000
Deferred rent (57,000) 20,000
Income taxes payable 0 (11,000)
Net cash (used in) provided by operating activities (270,000) (455,000)
Cash flows from investing activities:    
Purchase of property and equipment (34,000) (426,000)
Net cash used in investing activities (34,000) (426,000)
Cash flows from financing activities:    
Proceeds from senior convertible note payable from related party 0 0
Payments on senior convertible note payable from related party 0 (500,000)
Proceeds from note payable to related party 0 250,000
Payments on note payable to related party (187,000) (63,000)
Principal payments on note payable and capital leases (188,000) (183,000)
Net cash used by financing activities (375,000) (496,000)
Net decrease in cash and cash equivalents (679,000) (1,377,000)
Cash and cash equivalents at beginning of year 1,151,000 2,528,000
Cash and cash equivalents at end of year 472,000 1,151,000
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 16,000 7,000
Cash paid for interest 6,000 62,000
Supplemental disclosure of non-cash investing activity:    
Company financed the purchase of certain insurance policies note $ 110,000 $ 136,000